- In June 2021, Philips made a voluntary recall of its sleep and respiratory aid devices.
- The latest FDA investigations identified further issues with its quality control processes. However, based on arguments from both sides, uncertainties about the future outcomes remain.
- Despite the issues in the respiratory care business, Philips has produced some of its best results since the start of its restructuring.
- The restructuring process is completed, marking the start of a new era in Philips history.
- I am very bullish about the future midterm prospect of Philips, as even the most adverse scenarios show little room for downside risk.
For further details see:
Philips: Recall Uncertainties Create Value Opportunity